Corporate calendar for Phio Pharmaceuticals Corp. (PHIO): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | $159M | |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | ||
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 |
Stock Splits
| Date | Ratio |
|---|---|
| 2024-07-05 | 1:9 |
| 2023-01-26 | 1:12 |
| 2020-01-15 | 1:55 |
| 2018-01-08 | 1:10 |
| 2016-04-18 | 1:10 |
| 2013-07-24 | 1:30 |
Price
| Price | $1.00 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Related companies: ACXP · APRE · APVO · BCDA · CELZ · GLTO · INAB
Explore sector: Healthcare · Biotechnology
More sections of PHIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks